Indications |
Intravenous Metastatic ovarian cancer Adult: As monotherapy: 100 mg/m2 per cycle, given as a single dose infused in 0.9% sodium chloride or glucose once every 4 wk. For combination therapy with cyclophosphamide: 75-100 mg/m2 on day 1 of every 4-wk cycle. Child: Renal impairment: Dose adjustment may be needed. Intravenous Metastatic testicular tumours Adult: 20 mg/m2 BSA daily for 5 days per cycle. Renal impairment: Dose adjustment may be needed. Intravenous Advanced bladder cancer Adult: 50-70 mg/m2 per cycle once every 3-4 wk, depending on the extent of prior exposure to radiation and/or chemotherapy treatment. An initial dose of 50 mg/m2 every 4 wk may be used in heavily pre-treated patients. Renal impairment: Dose adjustment may be needed. Incompatibility: Y-site incompatibility: Thiotepa, cefepime, amphotericin B, amifostine, piperacillin/tazobactam, cholesteryl sulfate complex. Admixture incompatibility: Mesna, thiotepa, fluorouracil. |
Contraindications |
Patients with severe renal or auditory disorder, known hypersensitivity, severe bone marrow suppression, peripheral neuropathy, pregnancy, lactation. |
Warnings / Precautions |
Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hr after admin to minimise nephrotoxicity. |
Adverse Reactions |
Severe nausea and vomiting. Serious toxic effects on the kidneys, bone marrows and ears. Hypomagnesaemia, hypocalcaemia, hyperuricaemia. Peripheral neuropathies, papilloedema, optic neuritis, seizures. Ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. Potentially Fatal: Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities. |
Overdose Reactions |
Acute overdosage may result in kidney failure, liver failure, deafness, ocular toxicity, significant myelosuppression, intractable nausea and vomiting and/or neuritis. Death may also occur following overdosage. Treatment should include general supportive measures. |
Drug Interactions |
Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ≤100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression. Potentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs. See Below for More cisplatin Drug Interactions |
Mechanism of Actions |
Cisplatin modifies cell cycle by interfering with DNA structure and function. Effects are most prominent during the S phase but cells are killed at all stages. Cisplatin synergises with other anticancer drugs e.g. fluorouracil. It has a narrow therapeutic margin and is highly toxic. Absorption: Well absorbed (intraperitoneal). Distribution: Concentrated in the liver, kidneys, large and small intestines; poor penetration into the CNS. Excretion: Urine. Elimination half-life: 25-49 min (initial), 58-73 hr (terminal). |
Storage Conditions |
Intravenous: Store at 15-25°C. |
ATC Classification |
L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer. |
Storage |
Intravenous: Store at 15-25°C. |
Available As |
|
Cisplatin
Post Review about Cisplatin Click here to cancel reply.
Cisplatin Containing Brands
Cisplatin is used in following diseases
Drug - Drug Interactions of Cisplatin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.